Recombinant Human Serum Albumin Production via Trigger Factor Chaperone
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant human serum albumin (rHSA) in E. coli host systems face challenges such as high aggregation of proteins, leading to inclusion bodies and low levels of functionally active soluble rHSA, which limits their therapeutic and biotechnological applications.
Innovation Solution
A process involving the co-expression of rHSA and the molecular chaperone Trigger Factor, along with osmolytes like trehalose, to optimize cellular growth conditions and cell lysis, resulting in a 20-30% increase in functionally active soluble rHSA protein levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If rHSA is produced in E. coli host system using conventional methods, then production cost is reduced and growth speed is increased, but protein aggregation occurs leading to inclusion bodies and low levels of functionally active soluble rHSA
Solution Approach 1:
The patent introduces molecular chaperones (Trigger Factor, GroEL, GroES, DnaK, DnaJ, GrpE) as intermediary proteins that assist in the proper folding of recombinant human serum albumin. These chaperones act as mediators between the synthesized rHSA and the cellular environment, preventing aggregation and facilitating correct conformation, thereby resolving the contradiction between high productivity and protein solubility/functional activity
Solution Approach 2:
The patent employs osmolytes (trehalose, sucrose, betaine, proline) to change the physical-chemical parameters of the cellular environment. These osmolytes modify the solvent properties and stabilize protein structures, preventing aggregation and enhancing the solubility and functional activity of rHSA while maintaining high production levels in E. coli
2Quantity of substance
If rHSA is expressed in E. coli, then large quantities of pathogen-free recombinant HSA can be produced economically, but more than 90% of expressed rHSA forms aggregates leading to inclusion bodies
Solution Approach 1:
Molecular chaperones are introduced as intermediary proteins that bind to nascent rHSA chains during translation and prevent aggregation. These chaperones facilitate proper folding and ensure that the majority of produced rHSA remains soluble and functionally active, directly addressing the manufacturing precision issue while maintaining high production quantity
Solution Approach 2:
The patent creates a composite cellular environment by co-expressing multiple chaperone proteins and adding osmolytes to the culture medium. This composite system of chaperones and osmolytes works synergistically to prevent aggregation and enhance solubility, enabling high-yield production of functional rHSA in E. coli
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enhances the solubility and functional activity of rHSA, achieving a 1.5-2.0 fold increase in soluble protein levels and 20-30% increase in functionally active rHSA, addressing the limitations of previous methods by promoting proper protein folding and reducing aggregation.
Implementation Method 1
obtain recombinant E. coli host cells co-expressing rHSA and Trigger factor (molecular chaperone)
Implementation Method 2
adding L-Arabinose (inducer of trigger factor) to the above culture medium at a concentration in the range of 0.3 to 0.6 mg/ml
Data Source
AI summary
The present disclosure provides a process for improved production and extraction of recombinant human serum albumin (rHSA) using E. coli as a host system. The process of the instant disclosure provides enhanced recovery of soluble and functional rHSA over conventional known methods.